The Lancet Rheumatology Publishes the Data from Prospective Study on DAVIX, the Surrogate Outcome Measure for Patients with Systemic Sclerosis
We are delighted to announce the publication of a research paper titled “MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study” in the Lancet Rheumatology (impact factor 25.4).
This study is a result of successful collaboration between the dedicated team of scientists, physicians and patients.
This groundbreaking study introduces DAVIX, a novel MRI-based surrogate outcome measure for digital ulcer disease in systemic sclerosis patients. This endpoint was developed by the team at the University of Leeds and Image Analysis Group.
This innovation presents a game-changing opportunity for biotech companies developing treatments for this challenging condition.
Key Benefits for Clinical Trial Operations:
-
Enhanced Patient Stratification: DAVIX’s ability to non-invasively predict future digital ulcers enables more precise patient selection, potentially reducing trial sizes and costs.
-
Early Efficacy Assessment: The semi-automated MRI technique allows for quantitative assessment of digital artery disease, facilitating early go/no-go decisions and potentially shortening trial durations.
-
Improved Outcome Measurement: DAVIX correlates with clinical parameters and patient-reported outcomes, offering a more objective and sensitive measure of treatment efficacy.
-
Multicenter Trial Compatibility: DAVIX demonstrates feasibility across different MRI magnets and geographical locations.
Strategic Advantages:
-
Risk Mitigation: Early efficacy assessments and predictive capabilities can significantly de-risk clinical development.
-
Accelerated Development: More sensitive outcome measures may lead to faster trial completion and earlier regulatory submissions.
-
Cost Efficiency: Improved patient stratification and earlier decision-making can optimize resource allocation.
By leveraging DAVIX and partnering with expertise in medical imaging, biotech companies can potentially accelerate their systemic sclerosis drug development programs, reduce investment risks, and bring innovative therapies to patients sooner.
‘It not only offers hope for systemic sclerosis patients through the introduction of DAVIX as a surrogate outcome measure but also aligns with the goals of early treatment response assessment in scleroderma drug development,’ commented Prof. del Galdo, PI on the study.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.